Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

by dyadic | Oct 25, 2023 | Press Releases

JUPITER, Fla., Oct. 25, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative...

Dyadic Appoints Doug Pace to Its Executive Leadership Team

by dyadic | Oct 9, 2023 | Press Releases

JUPITER, Fla., Oct. 09, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative...

Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases

by dyadic | Oct 5, 2023 | Press Releases

JUPITER, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative...

Dyadic to Present at Industry and Investor Events in October

by dyadic | Sep 29, 2023 | Press Releases

JUPITER, Fla., Sept. 29, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for...

Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells

by dyadic | Sep 26, 2023 | Press Releases

JUPITER, Fla. and PARIS, Sept. 26, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS (“bYoRNA”) today announced that they entered into a development and commercialization agreement to work on...